A collaborative study from the Academic GI Cancer Consortium (AGICC) has been published in The Oncologist, reporting results from a multicenter Phase II trial evaluating FOLFOXIRI plus panitumumab as first-line therapy for patients with left-sided, RAS wild-type metastatic colorectal cancer.
The study demonstrated a 74% objective response rate, 96% disease control rate, and median progression-free survival of 17 months, with the authors reporting response and progression-free survival outcomes among the highest reported in stage IV colon cancer.
Continue reading
